Suboxone tooth decay lawsuit: where MDL 3092 actually stands heading into bellwether trials
The Suboxone tooth decay litigation tests whether a manufacturer can be held liable for failing to warn about serious dental injuries from a drug that was approved more than two decades ago. MDL 3092 (In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation), centralized in the U.S. District Court for the Northern District of Ohio before Judge J. Philip Calabrese, consolidates more than 11,000 federal lawsuits as of mid-2026 alleging that Suboxone sublingual film caused severe tooth decay, enamel erosion, cavities, and tooth loss in patients using the medication for opioid use disorder treatment. The case theory focuses on the acidic formulation of the dissolving film and the manufacturers' alleged failure to warn about dental risks for more than a decade after they became aware of the problem.
The substantive case centers on the timing of warnings. Suboxone was approved by the FDA in 2002 for treatment of opioid use disorder. The sublingual film formulation was introduced in 2010 as a more convenient alternative to the original tablet. The acidic formulation, which dissolves directly in the patient's mouth over several minutes during regular use over years, was linked to dental damage in mounting adverse event reports starting shortly after the film's introduction. Internal documents produced through discovery suggest Indivior received reports of dental damage as early as 2011-2012, but the FDA-required label warning about severe dental injury wasn't added until June 2022 — more than a decade after the film's introduction and more than twenty years after the original drug's approval.
The litigation is procedurally distinctive for its size. With over 11,000 federal cases and an additional 20,000+ plaintiffs joined through Judge Calabrese's "block filing" mechanism (allowing up to 100 plaintiffs per complaint), MDL 3092 is one of the largest active pharmaceutical mass torts. The bellwether trial framework is developing on an extended timeline — the court is narrowing 500 cases in the Records Collection Pool down to four final bellwether cases by June 11, 2027, with the first bellwether trial projected for March 2028. The extended timeline reflects the complexity of medical record collection for thousands of plaintiffs with complex dental treatment histories.
This is the science behind the Suboxone-tooth decay connection, the procedural history of MDL 3092, the eligibility framework for filing claims, the bellwether trial framework, and the strategic considerations for current and prospective plaintiffs.
What Suboxone is and what it does
Suboxone is a prescription medication combining two active ingredients used in medication-assisted treatment (MAT) for opioid use disorder:
Buprenorphine. A partial opioid agonist that activates opioid receptors but to a lesser extent than full agonists like heroin or oxycodone. Buprenorphine helps reduce opioid cravings and withdrawal symptoms without producing the same euphoric effects.
Naloxone. An opioid antagonist that blocks opioid receptors. In Suboxone, naloxone is included primarily to deter misuse — if the medication is injected rather than taken sublingually, naloxone activates and causes withdrawal symptoms.
The combination is designed for the dissolving sublingual route. When taken as directed (placed under the tongue or inside the cheek to dissolve), the buprenorphine is absorbed and provides therapeutic effect while the naloxone has minimal absorption.
The drug's history:
2002 FDA approval. Suboxone tablet form approved by the FDA for treatment of opioid use disorder.
2010 Suboxone film introduction. Reckitt Benckiser (Indivior's predecessor) introduced the Suboxone sublingual film formulation. The film is placed in the mouth and dissolves over several minutes, releasing buprenorphine and naloxone for absorption.
2014 Indivior spin-off. Reckitt Benckiser spun off Indivior as a separate company. Indivior took over Suboxone manufacturing and distribution. Reckitt Benckiser remained involved in earlier products and faces some related liability.
2010s adverse event reports. Reports of dental damage from Suboxone film users began emerging in the early 2010s. The reports involved severe tooth decay, enamel erosion, gum infections, and tooth loss in patients with previously healthy teeth.
June 2022 FDA label update. The FDA required Indivior to update the Suboxone label to include warnings about severe dental injury. The warning added information about tooth decay, cavities, oral infections, and tooth loss reported in patients taking transmucosal buprenorphine products. The label warning came more than a decade after the film's introduction and after extensive evidence of dental damage had accumulated.
2022 JAMA study. A peer-reviewed study published in JAMA Internal Medicine found that patients taking sublingual buprenorphine experienced more than twice the rate of dental issues compared to other forms of buprenorphine administration. The study provided scientific foundation for the connection between Suboxone film specifically and dental damage.
The plaintiffs allege Indivior and Aquestive Therapeutics knew of the dental risks based on adverse event reports from at least 2011-2012 but continued marketing the film without adequate warnings until forced by FDA action in 2022.
The dental damage mechanism
The connection between Suboxone film and tooth decay involves multiple mechanisms:
Highly acidic formulation. Suboxone film has a pH around 3.4 — comparable to citric acid or vinegar. Direct prolonged contact with this acidic environment damages tooth enamel through demineralization, similar to the effects of constant exposure to acidic foods or beverages.
Sustained mouth contact. The film dissolves over several minutes during normal use, with the patient placing it directly against teeth and gum tissue. This prolonged contact pattern produces sustained acidic exposure that brief acid exposure (from food/drink) doesn't replicate.
Daily use over years. Patients in opioid use disorder treatment typically use Suboxone daily for months to years. The cumulative effect of daily acidic exposure over extended periods produces substantial total dental damage.
Reduced salivary flow. Some opioid medications including buprenorphine reduce salivary flow. Decreased saliva removes the body's natural mechanism for neutralizing acidic exposure and remineralizing teeth, compounding the damage.
Tooth-specific impact. The film typically contacts the teeth in specific locations (typically lower incisors and adjacent teeth depending on placement habits). The damage pattern tends to concentrate in those specific teeth rather than affecting all teeth uniformly.
The dental injuries alleged in MDL 3092:
Severe tooth decay (caries). Rapid decay affecting multiple teeth, often in patients with previously healthy dental records.
Enamel erosion. Loss of the protective tooth enamel layer, leading to tooth sensitivity, structural weakness, and exposure to further damage.
Cavities requiring extensive dental work. Multiple cavities developing simultaneously, often requiring root canals, crowns, and similar extensive interventions.
Gum infections (periodontal disease). Infections of the gum tissue and underlying structures supporting the teeth.
Tooth fractures. Teeth weakened by erosion can fracture under normal use forces.
Root canal procedures. Decay extending into tooth roots requires root canal treatment in many cases.
Tooth loss and extractions. Severe damage often requires extraction of affected teeth. Some plaintiffs have lost most or all of their teeth.
Need for dentures or implants. Complete tooth loss requires dentures or dental implants, with substantial cost and ongoing maintenance.
The financial cost of treating Suboxone-related dental damage can be substantial — comprehensive treatment plans involving multiple extractions, implants, crowns, and ongoing maintenance can cost $50,000-$200,000+ depending on the extent of damage and treatment choices.
The procedural history of MDL 3092
The litigation has developed:
Early 2023. First Suboxone tooth decay lawsuits filed in various federal courts.
February 2024. JPML created MDL 3092 to consolidate Suboxone dental injury cases in the Northern District of Ohio before Judge J. Philip Calabrese.
Mid-2024. Initial discovery phase began. Plaintiff leadership structure approved. Document production from Indivior and Aquestive Therapeutics commenced.
January 2025. Court partially denied Indivior's motion to dismiss. Design defect and failure-to-warn claims survived dismissal, allowing the cases to proceed.
May 2025. Court allowed "block filing" of hundreds of claims in single complaints. The procedural innovation allows up to 100 plaintiffs per complaint, dramatically accelerating filing for tens of thousands of potential plaintiffs.
May 2025. Court designated 500 cases for Records Collection Pool to gather medical and dental evidence.
Summer 2025. Bellwether case pool narrowed. Discovery continued including document production, depositions, and expert work.
October 2025. Court ordered Indivior and Aquestive to produce extensive internal records including FDA filings, marketing materials, and adverse event reports.
December 2025. 400 plaintiffs from the Records Collection Pool selected for case-specific medical and dental evidence collection.
Throughout 2025-2026. Indivior sent record requests to 6,431 plaintiffs' medical providers. Defendants produced 5,920 record sets totaling 257,113+ pages.
December 17, 2025. Year-end case management conference. Court reviewed status and outlined 2026 path toward bellwether trials.
Throughout 2026. Monthly case management conferences (January, February, July, plus virtual status hearings) addressing discovery, expert selection, and procedural matters.
Projected timeline going forward:
- 500 case pool → 100 cases → 15 cases → 5 final bellwethers
- Dispositive motions due March 12, 2027
- 4 final bellwether cases selected by June 11, 2027
- First bellwether trial projected March 2028
The extended timeline reflects the substantial work required for thousands of plaintiffs with complex dental histories that need individual documentation and expert review. The size of the litigation (11,000+ cases, 20,000+ effective plaintiffs through block filing) is one of the largest pharmaceutical mass torts currently in active pretrial development.
Eligibility framework
The framework for filing Suboxone tooth decay claims:
Documented Suboxone film use. Records showing the claimant used Suboxone sublingual film (not tablets or other formulations). Prescription records, pharmacy records, treatment program records, or insurance records.
Duration of use. Typically requires substantial duration of use (months to years) to establish causation. Brief Suboxone use is less likely to produce the cumulative dental damage that supports the case theory.
Diagnosed qualifying dental injury. Medical and dental records establishing one of the qualifying conditions:
- Severe tooth decay requiring extensive treatment
- Enamel erosion documented through dental examinations
- Multiple cavities developed during or after Suboxone use
- Tooth loss or extractions required because of decay or erosion
- Periodontal disease developed during Suboxone use
- Need for dentures or implants because of Suboxone-related damage
Temporal proximity. The dental damage emerged during or shortly after Suboxone use. Pre-existing significant dental disease (substantial pre-Suboxone decay) weakens the case substantially.
Pre-Suboxone dental baseline. Records showing dental condition before starting Suboxone help establish that the damage developed during use rather than predating it. Patients with comprehensive pre-Suboxone dental documentation typically have stronger cases.
Statute of limitations compliance. State-specific limitations periods apply, typically 2-3 years from injury or discovery. Many states' deadlines are approaching for patients who used Suboxone in 2020-2022 timeframe. Timely filing is increasingly important.
No significant alternative causation. Cases involving strong alternative causes for dental damage (untreated diabetes, severe eating disorders, methamphetamine use, etc.) face more difficult causation analysis. The plaintiff doesn't need to show Suboxone was the sole cause, but the case is stronger when alternative causes are less prominent.
The strongest typical case profile:
A patient who used Suboxone sublingual film daily for 2+ years, had healthy pre-treatment dental status documented through routine dental care, developed severe tooth decay affecting multiple teeth during or shortly after treatment, required extensive dental work including extractions and prosthetics, has comprehensive medical and dental records establishing the timeline, and has no significant alternative causation.
Settlement projections
While no global settlement has been reached, estimates from plaintiffs' counsel:
Settlement range. Various estimates suggest $50,000 to $400,000+ per case for typical cases, with severe cases (extensive tooth loss, expensive prosthetic treatments, related medical complications) potentially exceeding the range.
Tiered compensation likely. Severity of dental damage, treatment costs incurred and projected, age at injury, and other factors will affect individual settlement amounts.
Bellwether trial influence. First bellwether trials projected for March 2028 will substantially affect settlement framework. Strong plaintiff verdicts could accelerate settlement; defense verdicts could delay or reduce settlements.
Time horizon for resolution. Given the extended bellwether timeline, global settlement (if reached) is likely 2-3 years away at minimum. Some plaintiffs may need to continue funding ongoing dental treatment during the wait for compensation.
Total litigation exposure. With 11,000+ cases and 20,000+ effective plaintiffs through block filing, total exposure could reach $5-15 billion depending on settlement framework. Indivior's market capitalization is approximately $1.6 billion as of mid-2026, raising questions about the company's ability to fund a comprehensive settlement.
How Suboxone compares to other mass torts
The litigation has distinctive features:
Compared to Zantac MDL 2924 where the federal MDL was dismissed: Zantac faced catastrophic Daubert exclusion. Suboxone has survived motion to dismiss with design defect and failure-to-warn claims intact.
Compared to Philips CPAP MDL 3014 which settled relatively quickly: Philips had clearer product defect and reached $1.1 billion settlement framework. Suboxone is proceeding through extended bellwether process.
Compared to Tepezza MDL 3079 also involving delayed FDA warnings: Both cases involve manufacturers who allegedly delayed warnings about serious adverse effects. Tepezza is smaller (~275 cases) with bellwether trials in 2026-2027; Suboxone is much larger (11,000+ cases) with bellwether trials in 2028.
Compared to Roundup litigation: Both involve products with substantial documented internal corporate knowledge of risks. Roundup is procedurally further along; Suboxone is earlier in its trajectory.
Compared to 3M Combat Arms with the $6 billion global settlement: 3M's case count was substantial (300,000+ claims). Suboxone is smaller in raw count but per-case values may be higher.
The broader procedural framework for mass tort settlements is detailed in our overview of how mass tort litigation works. Suboxone represents one of the largest active pharmaceutical mass torts with substantial expected resolution value when the framework matures.
Strategic considerations
For potential plaintiffs:
Don't delay filing. State statutes of limitations are approaching for many potential plaintiffs. Patients who used Suboxone in 2020-2022 timeframe face deadlines throughout 2026 in states with 2-year limitations periods. The discovery rule may extend limitations in some cases but has limits. Early filing preserves claim viability.
Use block filing mechanism if appropriate. Judge Calabrese's block filing order allows up to 100 plaintiffs per complaint, dramatically simplifying filing for plaintiffs working with the same firm. The mechanism doesn't reduce per-case settlement values but accelerates getting into the MDL.
Engage Suboxone-experienced counsel. The MDL framework is procedurally specific. Firms with established Suboxone case books typically handle cases more effectively. Most plaintiffs' firms work on contingency basis (typically 30-40% of recovery).
Obtain comprehensive medical and dental records. Records of pre-Suboxone dental status, treatment received during Suboxone use, post-Suboxone dental work, and similar documentation are essential. The case strength depends substantially on documentation quality.
Document the treatment timeline carefully. Detailed records of Suboxone prescriptions, treatment programs, dosing patterns, and duration of use. Coordinate with treating physicians and dental providers to ensure comprehensive documentation.
Be realistic about timeline. First bellwether trials projected for March 2028. Settlement framework, if reached, may emerge in 2028-2029. Plan for extended litigation timelines. Continuing dental treatment during the wait may be necessary for many plaintiffs.
Coordinate with ongoing dental care. Documentation of dental treatment costs and projected future treatment supports settlement valuation. Working with dental providers who understand the litigation framework helps ensure documentation captures relevant information.
Watch for additional defendants. Beyond Indivior and Aquestive, related parties including Reckitt Benckiser (Indivior's predecessor) face potential liability for pre-2014 conduct. Comprehensive claims should evaluate all responsible parties.
Don't accept inadequate settlements. Some firms may offer early settlements for amounts substantially below typical projections. Have any settlement offer evaluated by experienced counsel before signing.
Consider Indivior's financial situation. Indivior's market capitalization (~$1.6 billion) raises questions about its ability to fund comprehensive settlement. Strategic considerations may include timing of resolution relative to other Indivior financial events.
The Suboxone tooth decay litigation represents accountability for a manufacturer who allegedly continued marketing a product with known dental risks for more than a decade after the risks became apparent. For patients who used Suboxone film during the unwarned period (2010-2022) and developed serious dental damage, the framework provides paths to compensation. The March 2028 bellwether trial timeline is extended but reflects the complexity of the litigation. For potential plaintiffs, engagement with experienced counsel, comprehensive medical and dental documentation, timely filing within applicable limitations periods, and patience with the extended timeline are the procedural steps that preserve eligibility for participation in whatever resolution framework ultimately emerges. The science is strong, the procedural framework is mature, and the litigation should produce meaningful resolution within the next 2-3 years.